Storytelling Intervention for African Americans Living With Hypertension

Sponsor
University of Delaware (Other)
Overall Status
Recruiting
CT.gov ID
NCT05594264
Collaborator
(none)
60
1
1
7
8.5

Study Details

Study Description

Brief Summary

Narrative communication (e.g., storytelling) is an approach that has contributed to behavioral change for individuals with conditions such as diabetes, breast cancer, and hypertension. The objective of this study is to conduct a feasibility and pilot study storytelling intervention for African Americans with hypertension. In the feasibility phase 30 African Americans with hypertension will be recruited to view nine patient stories and provide feedback on the effectiveness, usefulness, and satisfaction with the stories. Nine African Americans adults with hypertension were filmed, sharing experiences living with and managing hypertension; including, diet and exercise tips, suggestions for locating healthy foods, and motivational stories about successfully controlling hypertension. During the feasibility phase feedback will also be elicited from the participants about the best approaches for delivering a storytelling intervention, and obtain feedback on the resources and health information that would be helpful to an individual participating in a storytelling intervention. In the pilot study phase, 30 African Americans adults with hypertension will be recruited to participate in a 6-week trial, each week the participants will watch one story and review one module of health information accessible through the study specific website developed for the HBPStories study. Data will be collected at baseline and 6-weeks including systolic and diastolic blood pressure, medication adherence, health behaviors such as diet and physical activity, and psychosocial measures including positive affect and self-efficacy in the management of hypertension.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: HBPStories
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Developing and Implementing a Storytelling Intervention for African Americans Living With Hypertension
Actual Study Start Date :
Jul 14, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Feb 13, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Web-based Storytelling

Participants will participate in a 6-week web-based storytelling study.

Behavioral: HBPStories
A 6-week web-based study. Systolic blood pressure, diastolic blood pressure, and medication adherence will be measured at baseline and 6-weeks.

Outcome Measures

Primary Outcome Measures

  1. Blood Pressure [6 weeks]

    Systolic and Diastolic Blood Pressure, Unit of Measure: Percentage of Individuals with Elevated or High Blood Pressure

  2. Medication Adherence [6 weeks]

    Self-reported using the DOSE-Nonadherence Scale, Unit of Measure: Percentage of Individuals reporting low, moderate, or high adherence

Secondary Outcome Measures

  1. Diet [6 week]

    Self-reported using the Assessment of Dietary Adherence and Identification of Barriers to Healthy Eating, Unit of Measure: Percent of participants reporting a healthy diet

  2. Physical Activity [6 week]

    Self-reported using the Yale Physical Activity Scale, Unit of Measure: Rates of physical inactivity

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
The study inclusion criteria are as follows:
  • self-reported hypertension

  • race/ethnicity: Black or African American

  • prescribed antihypertensive medication

  • age ≥ 18 years

Exclusion Criteria:
The exclusion criteria are:
  • cognitive limitations that limit the ability to provide informed consent

  • unable to speak or read English

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Delaware Newark Delaware United States 19713

Sponsors and Collaborators

  • University of Delaware

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Delaware
ClinicalTrials.gov Identifier:
NCT05594264
Other Study ID Numbers:
  • 1766419-7
First Posted:
Oct 26, 2022
Last Update Posted:
Oct 26, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Delaware
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2022